New Asthma Treatment Approved: Just 2 Doses Per Year

Living with severe asthma means constant vigilance, daily medications, and the fear that your next breath might not come easily. But a newly approved treatment could change everything for hundreds of thousands of people across Europe who face this reality every day.

The European Commission just approved Exdensur (depemokimab), the first ultra-long-acting biologic treatment for severe asthma and chronic rhinosinusitis with nasal polyps. What makes it revolutionary is simple: patients need just two doses per year instead of daily medications or frequent injections.

GSK Ireland has already submitted an application for reimbursement to Irish health officials. If approved, around 450,000 people in Ireland currently living with asthma could potentially benefit from this innovation, especially the 3 to 10 percent with severe forms of the disease.

The treatment targets severe asthma with type 2 inflammation in adults and adolescents 12 and older who aren't getting relief from high-dose inhaled corticosteroids. It also helps adults with severe chronic rhinosinusitis with nasal polyps when other treatments like surgery or systemic corticosteroids haven't worked.

Four major clinical trials called SWIFT and ANCHOR proved the medication works. Each trial showed statistically significant and clinically meaningful improvements when depemokimab was added to standard care compared to standard care alone.

Dr. Richard Costello, a consultant respiratory physician at Beaumont Hospital, called it "a new era in innovation in asthma care." He said the treatment promises to reduce the burden of constant medication while delivering meaningful clinical outcomes for patients with severe asthma.

Why This Inspires

This approval represents more than just medical progress. It's about freedom for people who've structured their entire lives around managing a chronic condition.

Imagine not having to remember daily medications or worry about running out during travel. Picture teenagers who can focus on school and friends instead of constant treatment schedules. Think about the relief of knowing a single injection will protect you for six months from severe breathing attacks that can land you in the emergency room.

Eilís Ní Chaithnía, CEO of the Asthma Society of Ireland, emphasized that timely access to licensed treatment options improves quality of life and long-term health outcomes. She welcomed the progress toward making this medicine available to Irish patients who need it.

The approval gives hope not just to current patients but to the estimated 900,000 individuals in Ireland expected to develop asthma over their lifetime. For millions across Europe facing inadequately controlled symptoms despite existing treatments, this ultra-long-acting option could mean breathing easier in every sense.

Kaivan Khavandi from GSK's research division said the treatment may help redefine care for millions living with these persistent and burdensome conditions, supporting them in achieving their treatment goals with unprecedented convenience.

Sometimes medical breakthroughs aren't just about new science but about making life genuinely livable for people who deserve to breathe freely.